CIPLA

Ciplas journey began in 1935 when our founder, Dr. K. A. Hamied, set up an enterprise with the vision to make India self-sufficient in healthcare. Over the past 77 years, we have emerged as one of the worlds most respected pharmaceutical names, not just in India but worldwide. We have 34 state-of-the-art manufacturing facilities that make Active Pharmaceutical Ingredients (APIs) and formulations, which have been approved by major international Regulatory Agencies. We have over 2000 products in 65 therapeutic categories; with over 40 dosage forms, covering a wide spectrum of diseases ranging from communicable, non-communicable, common and emerging diseases to even rare diseases. Our Research and Development (R&D) centre is focused on developing innovative products and drug delivery systems, giving the country and the world many Firsts'. Today, we are one of the worlds largest generic pharmaceutical companies with a strong presence in over 170 countries. We maintain world-class quality across all our products and services. Whether its for millions or for just a few hundreds, our journey to care for all humanitycontinues. Milestones

In 1935, our founder, Dr. K. A. Hamied set up Cipla to make India self-reliant in healthcare.

In 1939, Mahatma Gandhi visited Cipla and inspired our founder to make essential medicines for the country, and strive for self-sufficiency. During World War II, when India was dependent on imported medicines and there was an alarming shortage of lifesaving drugs, we manufactured them for the country.

In the 1960s, we pioneered API manufacturing in the country and helped lay the foundation for the bulk drug industry in India.

In 1970, we spearheaded the New Patent Law by which an Indian pharmaceutical company was allowed to manufacture a patented product as long as the process to manufacture it was changed. This enabled Indian companies for the first time to manufacture any medicines and make them available and affordable for all Indians.

In 1978, we pioneered inhalation therapy in India with the manufacture of MeteredDose Inhaler (MDI), at a time when the country stopped receiving imported supplies. Today, we have the worlds largest range of inhaled medication and devices. In 1994, we launched Deferiprone, the worlds first oral iron chelator which revolutionized the treatment for thalassemia. For the first time patients with thalassemia had an option that was affordable, painless and convenient.

In 1996, we gave the world the first transparent dry powder inhaler which was so simple and easy to use, it changed the face of inhalation therapy in India.

In 2001, we pioneered the access to HIV treatment by making antiretrovirals (ARVs) available at less than a Dollar a Day'. The cost of treatment dramatically fell from $12,000 per patient per year to $300 per patient per year. This caused a revolution where HIV treatment became a reality for the world and millions of lives could be saved.

During the 2005 Bird Flu epidemic, we produced an anti-flu drug within a period of 2-3 months, which would have normally taken at least 3 years to develop.

In 2012, we made a breakthrough in reducing the prices of cancer drugs, thus making world-class medicines affordable and accessible to cancer patients.

We are committed to addressing the unmet medical needs of the world by venturing into newer challenges in platform technologies, biotechnology and stem cells.

Global business We have a global presence in over 170 countries through exports and strategic alliances. Our exports include raw materials, intermediates, prescription drugs, OTC and veterinary products. We have partnerships/alliances for product development, technical support and marketing, and help several developing countries in their quest for self-reliance. We are known for our uncompromising quality standards in all our products and services, across the world. Board Of Directors
Founder
Dr. K.A.Hamied (1898-1972)

Chairman
Dr. Yusuf K Hamied

Executive Vice-Chairman
Mr. M.K. Hamied

Managing Director and Global Chief Executive Officer

Mr. Subhanu Saxena

Whole-time Director
Mr. S. Radhakrishnan

Non-Executive Directors
Dr. H.R.Manchanda Mr. V.C.Kotwal Mr. M.R.Raghavan Mr. Pankaj Patel Mr. Ashok Sinha

Corporate Social Responsibility Being a good corporate citizen is an integral part of our core value - caring for life.

The Cipla Palliative Care and Training Centre in Pune continues to provide holistic care to terminally ill cancer patients and their families free of charge. Till now the Centre has given treatment, comfort and solace to more than 7,700 patients. The focus of the Cipla Palliative Care Centre is to reach out to more cancer patients who need Palliative Care and to integrate Palliative medicine with curative therapy.

We extend support to Manavya, a Pune-based organization which runs a home for children with HIV infection. Manavya operates a mobile dispensary in villages on the outskirts of Pune and it is fully funded by the company.

On the occasion of Ciplas Platinum Jubilee in 2010, we set up the Cipla Foundation by contributing a sum of Rs. 5 crore. The Foundation aims to provide care and financial support to people in need of healthcare and education in India.

In a humanitarian effort to support cancer patients and relieve their burden, we made a breakthrough in reducing the prices of cancer drugs, thus making world-class medicines accessible to patients in India.

We work closely with several reputed non-profit organizations such as Drugs for Neglected Diseases Initiative, Medecins Sans Frontieres and the Clinton Foundation in order to make drugs for malaria, HIV/AIDS and several neglected diseases, available at affordable prices. We also provide medicines to treat over a million poor, aged patients in slums and villages through non-profit organizations. In addition, we support several health, educational and welfare activities in communities surrounding the companys factories, both directly and through our Charitable Trusts, by providing healthcare education, improvement of community infrastructure, scholarships, etc. This is part of our commitment to improve the quality of life for these communities. Reason for Choosing this Company Clipa is one of retain company which performing good in pharmaceutical industry. Cipla's Research & Development (R&D) is focused towards developing new products, improving existing products as well as drug delivery systems and expanding product applications. Hundreds of scientists work on all facets of pharmaceutical development and technology.